EVALUATION OF NITRIC OXIDE AND MALONDIALDEHYDE LEVELS IN SERUM OF EGYPTIAN PATIENTS WITH BLADDER AND RENAL TUMORS: POTENTIAL USE AS MEDICINAL BIOMARKERS
Mohamed El-Far*, Hassan Abol-Enein, Ashraf Zakaria and Mohammed El-Gedamy
ABSTRACT
The aim was to investigate the levels of malondialdehyde (MDA) and
nitric oxide (NO) in sera of patients with renal and bladder tumors and
to correlate their levels with tumor grade and stage. The study
consisted of 50 patients with bladder cancer, 50 renal cancer and 50
controls. NO levels were measured by the Griess reaction method.
MDA was measured by the thiobarbituric acid method. Serum NO
level was significantly higher (P < 0.001) in bladder cancer patients
while its level decreased in renal cancer patients (P < 0.001) than
controls. The previous observations suggest the over expression of NO
enzyme activity in bladder cancer, while its activity is down-regulated by renal cancer. In
renal tumor, NO levels were significantly diminished concomitant with advancing grades (P
= 0.028). On contrary, NO levels were significantly higher in patients with high grade
bladder tumors than moderate grade tumors (P = 0.049). Hence, these findings suggest the
utility of NO in inspecting the tumor development as a serum-based biomarker. Moreover,
the result demonstrated that, there was significantly increased in MDA level in both bladder
(P < 0.001) and renal (P < 0.001) cancer patients compared to the controls, which indicated
the appearance of lipid peroxidation due to the cancer oxidative damage. A significant
negative correlation was observed between NO and MDA concentrations in the serum of renal cancer patients (r = - 0.414, P = 0.003). The study showed no significant difference in
MDA and NO levels between the early and late stages.
Keywords: Bladder & renal cancer; MD A& NO; grade & stage; antioxidants & oxidative stress; medicinal biomarkers.
[Download Article]
[Download Certifiate]